Vimarsana
Biggest News Aggregation in the World

Page 9 - Realtime Dynamix News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Realtime Dynamix. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Realtime Dynamix Today - Breaking & Trending Today

Bristol Myers Squibb's Zeposia Launch Trajectories Diverge in Germany and the UK Following Negative NICE Decision; Janssen's Ponvory Could Likewise Stumble, According to Spherix Global Insights - Vimarsana News

Bristol Myers Squibb's Zeposia Launch Trajectories Diverge in Germany and the UK Following Negative NICE Decision; Janssen's Ponvory Could Likewise Stumble, According to Spherix Global Insights

/PRNewswire/ -- Following the May 2020 European Medicines Agency (EMA) approval of Bristol Myers Squibb's Zeposia and the May 2021 approval of Janssen's...

Bristol Myers Squibb's Zeposia Launch Trajectories Diverge in Germany and the UK Following Negative NICE Decision; Janssen's Ponvory Could Likewise Stumble, According to Spherix Global Insights - Vimarsana News

Bristol Myers Squibb's Zeposia Launch Trajectories Diverge in Germany and the UK Following Negative NICE Decision; Janssen's Ponvory Could Likewise Stumble, According to Spherix Global Insights

/PRNewswire/ -- Following the May 2020 European Medicines Agency (EMA) approval of Bristol Myers Squibb's Zeposia and the May 2021 approval of Janssen's...

Amgen's Aimovig and Eli Lilly's Emgality Feel the Heat From Strong Uptake of Biohaven's Nurtec ODT Among Primary Care Physicians for Migraine Prevention, According to Spherix Global Insights - Vimarsana News

Amgen's Aimovig and Eli Lilly's Emgality Feel the Heat From Strong Uptake of Biohaven's Nurtec ODT Among Primary Care Physicians for Migraine Prevention, According to Spherix Global Insights

/PRNewswire/ -- Following the May 2021 FDA approval of Biohaven's Nurtec ODT for the preventive treatment of episodic migraine, primary care physicians (PCPs)...

SGLT2 Inhibitors Poised to Potentially Reshape Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD) Patient Care After AstraZeneca's Farxiga Approval - Vimarsana News

SGLT2 Inhibitors Poised to Potentially Reshape Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD) Patient Care After AstraZeneca's Farxiga Approval

/PRNewswire/ -- Nephrologists have long considered chronic kidney disease (CKD) progression and diabetic kidney disease (DKD) as areas in dire need of new and...

As SGLT2 Inhibitors Create Increased Market Complexities for Chronic Kidney Disease Non-Dialysis Patients, How Quickly Will Patient Care Evolve - Vimarsana News

As SGLT2 Inhibitors Create Increased Market Complexities for Chronic Kidney Disease Non-Dialysis Patients, How Quickly Will Patient Care Evolve

Share this article Share this article EXTON, Pa., March 4, 2021 /PRNewswire/ -- Chronic kidney disease (CKD) patients experience a wide range of comorbidities and risks associated with their disease, such as diabetic complications, hyperkalemia, and metabolic acidosis. At the American Society of Nephrology (ASN) fall 2020 conference, Kidney Week Reimagined, news about SGLT2 inhibitors for CKD patients with and without diabetes created a stir and caused optimism about potential paradigm shifts for CKD patients. The fierce competition between AstraZeneca and Vifor/Relypsa in the hyperkalemia...